SOX2 mediates metabolic reprogramming of prostate cancer cells by de Wet, Larischa, Williams, Anthony, Gillard, Marc, Kregel, Steven, Lamperis, Sophia, Gutgesell, Lisa C., Vellky, Jordan E., Brown, Ryan, Conger, Kelly, Paner, Gladell P., Wang, Heng, Platz, Elizabeth A., De Marzo, Angelo M., Mu, Ping, Coloff, Jonathan L., Szmulewitz, Russell Z., Vander Griend, Donald J.

Get full text

ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature by Vellky, Jordan E, Kirkpatrick, Brenna J, Gutgesell, Lisa C, Morales, Mathias, Brown, Ryan M, Wu, Yaqi, Maienschein-Cline, Mark, Notardonato, Lucia D, Weinfeld, Michael S, Nguyen, Ryan H, Brister, Eileen, Sverdlov, Maria, Liu, Li, Xu, Ziqiao, Kregel, Steven, Nonn, Larisa, Vander Griend, Donald J, Reizine, Natalie M

Get full text

Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells by de Wet, Larischa, Williams, Anthony, Gillard, Marc, Kregel, Steven, Lamperis, Sophia, Gutgesell, Lisa C., Vellky, Jordan E., Brown, Ryan, Conger, Kelly, Paner, Gladell P., Wang, Heng, Platz, Elizabeth A., De Marzo, Angelo M., Mu, Ping, Coloff, Jonathan L., Szmulewitz, Russell Z., Vander Griend, Donald J.

Get full text

SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis by Williams, Anthony, Gutgesell, Lisa, de Wet, Larischa, Selman, Phillip, Dey, Arunangsu, Avineni, Mahati, Kapoor, Isha, Mendez, Megan, Brown, Ryan, Lamperis, Sophia, Blajszczak, Chuck, Bueter, Eric, Kregel, Steven, Vander Griend, Donald J., Szmulewitz, Russell Z.

Get full text

Clonidine and electrocardiograms by Blackman, J A, Samson-Fang, L, Gutgesell, H

Get full text